ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Sun Pharmaceutical Industries Ltd.

Company Background

Sun Pharmaceutical is India's largest drugmaker. It sells mainly generic drugs, an area in which Indian companies do well, in more than 150 countries, including the U.S. It has over 20 production bases around the world and supplies more than 1,000 products. It has succeeded in expanding its business globally, given that domestic sales account for only about 30% of its group sales. It has built a solid business base especially in the U.S., generating more around 50% of sales in that market.

 

The company was founded in 1983 by Dilip Shanghvi, who serves as managing director. It brought online its first active pharmaceutical ingredients factory in the western Indian state of Gujarat in 1995. It has been on a growth path recently on the back of the global expansion of India's generic drug business. Shanghvi is known for his aggressive merger and acquisition strategy and has expanded his company through buyouts including overseas companies. In 2014, it bought Ranbaxy Laboratories, an Indian drugmaker, which cemented its place at the top of India's pharmaceutical industry.

 

Shanghvi and other founding family members and affiliate companies own more than 60% of shares in Sun Pharmaceutical. Shanghvi is one of India's richest men, and he and his family are actively investing in India.

Business Summary

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2021 INRUSD
Revenue334,981.40M4,512.44M
Gross Profit140,851.90M1,897.37M
Operating income64,988.60M875.44M
Income before tax27,993.70M377.09M
Net income29,038.20M391.16M
EBITDA85,788.10M1,155.62M
Diluted EPS12.100.16
Dividends Per Share7.500.10
Total Assets688,224.80M9,413.06M
Total liabilities193,426.50M2,645.55M
Total equity464,627.80M6,354.86M
Operating cash flow62,354.80M839.96M
Currency in INRCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 313,081.40M 264,155.40M 290,659.10M 328,375M 334,981.40M
Gross Profit 158,651.20M 109,049.50M 122,523.20M 140,938.30M 140,851.90M
Operating income 84,884.50M 41,097.80M 49,220M 52,395.30M 64,988.60M
Income before tax 90,478.70M 34,789.80M 38,102M 50,095.90M 27,993.70M
Net income 69,643.70M 20,957M 26,654.20M 37,649.30M 29,038.20M
EBITDA 97,532M 56,096.20M 66,752.50M 72,923.10M 85,788.10M
Diluted EPS 29 8.73 11.10 15.69 12.10
Dividends Per Share 3.50 2 2.75 4 7.50
Total Assets 619,117.90M 645,163.50M 646,938.10M 682,524.60M 688,224.80M
Total liabilities 214,674.70M 223,180.80M 199,712.10M 191,277.70M 193,426.50M
Total equity 366,396.70M 383,141.10M 414,090.60M 452,644.50M 464,627.80M
Operating cash flow 71,269.50M 39,781.60M 24,425.10M 66,775.20M 62,354.80M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 4,668.88M 4,097.58M 4,155.67M 4,631.13M 4,512.44M
Gross Profit 2,365.91M 1,691.58M 1,751.76M 1,987.67M 1,897.37M
Operating income 1,265.85M 637.51M 703.71M 738.94M 875.44M
Income before tax 1,349.27M 539.66M 544.76M 706.51M 377.09M
Net income 1,038.57M 325.08M 381.08M 530.97M 391.16M
EBITDA 1,454.46M 870.16M 954.38M 1,028.44M 1,155.62M
Diluted EPS 0.43 0.13 0.15 0.22 0.16
Dividends Per Share 0.05 0.03 0.03 0.05 0.10
Total Assets 9,534.42M 9,891.85M 9,338.69M 9,021.98M 9,413.06M
Total liabilities 3,305.99M 3,421.87M 2,882.88M 2,528.41M 2,645.55M
Total equity 5,642.51M 5,874.44M 5,977.48M 5,983.30M 6,354.86M
Operating cash flow 1,062.81M 617.09M 349.21M 941.74M 839.96M

Valuation Measures

Mar 2021
PER49.37
ROA4.23%
ROE6.33%
Operating margin19.40%
Profit margin8.66%

Key executives

  • Managing Director & Executive Director: Dilip Shantilal Shanghvi
  • Executive Vice President-Global Operations: Davinder Singh
  • Chief Financial Officer: C. S. Muralidharan
  • SVP & Chief Information Officer: Atanu Roy
  • Compliance Officer & Senior GM-Secretarial: Ashok I. Bhuta

Shareholders

  • Shanghvi Finance Pvt Ltd. (41.9%)
  • SHANGHVI DILIP SHANTILAL (9.5%)
  • Life Insurance Corp of India (7.3%)
  • ICICI Prudential Asset Management Co. Ltd. (2.9%)
  • SBI Funds Management Pvt Ltd. (2.0%)
  • The Vanguard Group, Inc. (1.4%)
  • VALIA RAKSHA SUDHIR (1.2%)
  • Lakshdeep Investments & Finance Pvt Ltd. (1.1%)
  • Nippon Life India Asset Management Ltd. (Invt Mgmt) (1.1%)
  • HDFC Asset Management Co. Ltd. (Invt Mgmt) (1.0%)

Contact Details

  • Website:http://www.sunpharma.com
  • Address: CTS No. 201 B/1, Sun House, Western Express Highway, Mumbai, 400063, India
  • Phone: +91.22.43244324

Related Companies

  • 3 Skyline LLC
  • Zenotech Laboratories Nigeria Ltd.
  • Zenotech, Inc.
  • Sun Pharmaceuticals Korea Ltd.
  • Sun Pharmaceuticals France SA
  • Sun Pharmaceuticals (SA) Pty Ltd.
  • Sun Pharmaceuticals Holdings USA, Inc.
  • Sun Pharmaceutical Peru SAC
  • Sun Pharmaceutical Industries SAC
  • Sun Pharmaceutical (Bangladesh) Ltd.
  • Sun Pharma Switzerland Ltd.
  • Sun Pharma Philippines, Inc.
  • Sun Pharma Holdings
  • Sun Pharma Healthcare FZE
  • Sun Pharma East Africa Ltd.
  • Sun Laboratories FZE
  • Sun Global Development FZE
  • Sun Farmaceutica do Brasil Ltda.
  • Softdeal Trading Co. Ltd.
  • Sun Pharmaceutical Industries OOO
  • Kakayu Co., Ltd
  • Rexcel Egypt LLC
  • Realstone Multitrade Pvt Ltd.
  • Ranbaxy Pharmaceuticals Ukraine LLC
  • Ranbaxy Pharmaceuticals (Pty) Ltd.
  • Ranbaxy Farmaceutica Ltda.
  • Ranbaxy (Thailand) Co., Ltd.
  • Ranbaxy (Poland) Sp zoo
  • Ranbaxy South Africa (Pty) Ltd.
  • PI Real Estate Ventures LLC

Competitors

  • Dr. Reddy's Laboratories Ltd.
  • ANI Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals, Inc. Class A
  • Zentiva SA
  • Biofrontera AG
  • Antares Pharma, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Nicox SA
  • Curis, Inc.
  • Oyster Point Pharma Inc
  • Fortress Biotech, Inc.
  • Bora Pharmaceuticals Co Ltd
  • Evolus, Inc.
  • Sol-Gel Technologies Ltd.
Last Updated on 18 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more